H.C. Wainwright BioConnect 2022
Dates:
Format: On-demand investor presentation beginning on
Fireside Chat:
Registration: www.hcwevents.com/bioconnect
About Entasis
Entasis is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including post Phase 3 sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.
Entasis Contacts | |
Company Contact | Investor Contact |
(781) 810-0114 | (929) 469-3859 |
kyle.dow@entasistx.com | bmackle@lifesciadvisors.com |
Media Contact | |
(215) 315 3143 | |
bwhelan@lifescicomms.com |
![](https://ml.globenewswire.com/media/ZGNkYmE0NGUtNzM2MC00OTIzLWI4YTgtNmZiMmQ4NWU0NDY0LTExMDc0MjQ=/tiny/Entasis-Therapeutics-Holdings-.png)
2022 GlobeNewswire, Inc., source